Study Finds Preterm Birth Risk Linked to Underlying Diabetes Rather Than Inadvertent GLP-1 Weight Loss Drug Exposure

New 2026 study finds no preterm birth risk for women using weight-loss drugs for obesity, but warns of risks for those with pre-existing diabetes.

By: AXL Media

Published: Mar 18, 2026, 8:36 AM EDT

Source: Information for this report was sourced from European Society of Human Reproduction and Embryology

Investigating the Impact of Periconceptional Drug Exposure

A landmark study published in Human Reproduction Open has addressed a growing concern in maternal health: the safety of GLP-1 receptor agonists when taken inadvertently during early pregnancy. As medications such as semaglutide and liraglutide surge in global popularity, many women are accidentally exposing embryos to these substances before realizing they have conceived. Researchers at Copenhagen University Hospital Hvidovre analyzed data from more than 750,000 pregnancies to determine if this exposure leads to adverse outcomes like pre-eclampsia or stillbirth. Their findings offer a nuanced perspective that distinguishes between the effects of the medication and the health of the mother.

The Role of Diabetes in Obstetric Complications

The most significant finding of the research is that the increased risk of preterm birth was exclusively tied to women using GLP-1 drugs to treat pre-existing diabetes. For this specific group, the risk of delivering before 37 weeks was 70% higher for those on liraglutide and 84% higher for those on semaglutide compared to the general population. However, when the researchers adjusted for the underlying condition, they discovered that women taking the same drugs for weight management faced no such elevation in risk. This suggests that the metabolic instability of diabetes, rather than the chemical properties of the drugs, is the primary driver of premature delivery.

Challenging Current Preconception Guidelines

Current medical guidance typically recommends that women stop taking GLP-1 medications at least eight weeks before attempting to conceive. Professor Henriette Svarre Nielsen, the study's lead author, noted that these recommendations were largely based on early-phase animal models rather than real-world human data. While the study does not suggest that the current eight week rule should be abandoned yet, it provides much needed evidence for clinicians who must counsel women who have already been exposed. The data suggests that for non-diabetic patients, an accidental dose in the early stages of pregnancy may not be the cause for alarm that was previously feared.